Skip to main content
Article thumbnail
Location of Repository

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

By Francesco Chiarelli and Daniele Di Marzio


Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care,
  2. (1997). Activators of PPAR-gamma have depot-specifi c effects on human preadipocyte diffentiation.
  3. (2005). Alpha, beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma.
  4. (1994). Altered gene expression for tumor necrosis factor-alfa and its receptor during drug and dietary modulation of insulin resistance.
  5. (2002). Antiinfl ammatory and antiarteriosclerotic effects of pioglitazone.
  6. (2007). Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta 1. Thromb Haemost,
  7. (2002). Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-infl ammatory adhesion molecules in human vascular endothelial cells.
  8. (2001). Critical roles of PPAR beta/delta in keratinocyte response to infl ammation. Genes Dev,
  9. (2004). diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care,
  10. (2001). Diseases of liporegulation: new perspective on obesity and related disorders.
  11. (2000). Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
  12. (2003). Effect of peroxisome proliferatoractivated receptor-delta and-gamma activators on vascular remodelling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol,
  13. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
  14. (1999). Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care,
  15. (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care,
  16. (2007). Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial
  17. (2002). Effects of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
  18. (1993). Endothelins: from receptors to medicine. Trends Pharmacol Sci,
  19. (1995). Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
  20. (2000). For the pioglitazone 027 study group: pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebocontrolled study. Clin Ther,
  21. (2001). for the Rosiglitazone Clinical Trials Study Group.
  22. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
  23. (2000). Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferators activated receptor beta (delta).
  24. (2000). Impaired glucose tolerance: the irrepressible alphacell? Diabetes Care,
  25. (2001). Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care,
  26. (2006). Insulin resistance and PPAR insulin sensitizers. Curr Opin Investig Drugs,
  27. (1998). Insulin resistance, impaired glucose tolerance and non-insulin dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res,
  28. (2002). Insulin-sensitising agents:beyond thiazolidinediones. Expert Opin Emerg Drugs,
  29. (2001). Modular of vascular infl ammation in vitro and in vivo by peroxisome proliferator activated receptoractivators.
  30. (2001). Nonhypoglycemic effects of thiazolidinediones.
  31. (2000). Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor.
  32. (2003). Peroxisome proliferator-activated receptors: vascular and cardic effects in hypertension.
  33. (2006). Peroxisome proliferatoractivated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am,
  34. (2003). Peroxisome proliferatoractivated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol,
  35. (2003). Peroxisome-prolifator-activated receptor delta activates fat metabolism to prevent obesity.
  36. (2000). Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
  37. (2006). Pioglitazone for type 2 diabetes mellitus.
  38. (2005). Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.
  39. (2005). Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension.
  40. (2000). PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab,
  41. (2001). PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.
  42. (2005). PPAR-gamma: a critical determinant of body fat distribution in humans and mice. Trends Cardiovasc Med,
  43. (2003). PPARdelta is a very lowdensity lipoprotein sensor in macrophages.
  44. (2005). PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.
  45. (2002). Preservation of pancreatic beta-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high risk hispanic women.
  46. (2001). Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
  47. (2006). Recent fi ndings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Invest Drugs,
  48. (2002). Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin.
  49. (2005). Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res,
  50. (2002). Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes, 51(Suppl 2):P-573:A142.
  51. (2004). Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
  52. (2000). Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus.
  53. (2004). Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med,
  54. (2000). Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther,
  55. (1999). Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo controlled study. Diabetes Obes Metab,
  56. (2001). Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
  57. (2000). Rosiglitazone short term monotheraphy lowers fasting and postprandial glucosze in patients with type 2 diabetes.
  58. (2003). Selective effects of pioglitazone on insulin androgen abnormalities in normo- and hyperinsulineamic obese patients with polycystic ovary sindrome. Hum Reprod,
  59. (2001). Selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
  60. (2002). Structure, endothelial function, cell growth, and infl ammation in blood vassels of angiotensina II-infused rats: role of peroxisome proliferator-acvtivated receptorgamma.
  61. (2001). Suppression of nuclear factorkappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-infl ammatory effect and a potential antiatherosclerotic effect in the obese.
  62. (2003). The clinical implications of endothelial dysfunction.
  63. (2004). The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
  64. (2007). The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. JAm Coll Cardiol,
  65. (2001). The hormone resistin links obesity to diabetes.
  66. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.
  67. (2000). The perils of portiliness: causes and consequences of visceral adiposity.
  68. (2002). the pioglitazone 014 study group.
  69. (1999). The PPARs and PXRs: nuclear xenobiotic receptors that defi ne novel hormone signalling pathways. Recent Prog Horm Res,
  70. (2000). The PPARs: fro orphan receptors to drug discovery.
  71. (2007). The record on rosiglitazone and risk of myocardial infarction.
  72. (2006). The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells.
  73. (2000). Thiazolidinedione hepatotoxicity: a class effect?
  74. (2004). Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin rsistance. Diabetes Obes Metab,
  75. (2003). Thiazolidinedione use, fl uid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation,
  76. (2001). Thiazolidinediones and liver toxicity. Diabetes Metab,
  77. (2003). Thiazolidinediones in diabetes: current status and future outlook.
  78. (2003). Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
  79. (2001). Thiazolidinediones increase plasma adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
  80. (1996). Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferatoractivated receptor-gamma.
  81. (1999). Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPAR on vascular endothelial function.
  82. (2003). Thiazolidinediones- some recent developments. Expert Opin Investig Drugs,
  83. (2004). Thiazolidinediones: a review of their mechanism of insulin sensitiziation, therapeutic potential, clinical effi cacy, and tolerability. Diabetes Technol Ther,
  84. (1998). Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
  85. (2001). Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.
  86. (2003). Usefulness of troglitazone administration to obese hyperglycaemic patients with nearnormoglycaemia. Diabetes Obes Metab,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.